← Back to Search

Virus Therapy

HB-302/HB-301 Therapy for Prostate Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Hookipa Biotech GmbH
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 2 years
Awards & highlights

Summary

This trial tests a new treatment using two specially designed viruses to help the immune system fight advanced prostate cancer that doesn't respond to standard treatments. The treatment aims to teach the immune system to recognize and destroy cancer cells. This approach uses viruses to selectively infect and destroy cancerous cells while sparing normal cells and tissues.

Who is the study for?
Men over 18 with metastatic castration-resistant prostate cancer, who've had treatment with androgen receptor inhibitors but no chemotherapy (except docetaxel in a specific setting). They must have bone metastasis, testosterone under a certain level, and an ECOG performance status of 0-1. Participants need to show disease progression after standard care.
What is being tested?
The trial is testing HB-302/HB-301 alternating therapy for advanced prostate cancer. It's divided into two phases: Phase 1 to find the safest dose and Phase 2 to confirm this dose's effectiveness on more participants.
What are the potential side effects?
While not specified here, potential side effects may include typical reactions to immunotherapy such as fatigue, flu-like symptoms, pain at injection site, allergic reactions or autoimmune responses where the body attacks its own cells.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Phase I
Phase II

Trial Design

1Treatment groups
Experimental Treatment
Group I: HB-302/HB-301 Alternating 2-Vector Therapy Intravenously (IV)Experimental Treatment1 Intervention
HB-302/HB-301 Alternating 2-Vector Therapy Intravenously (IV)

Find a Location

Who is running the clinical trial?

Hookipa Biotech GmbHLead Sponsor
7 Previous Clinical Trials
878 Total Patients Enrolled
Chief Medical OfficerStudy DirectorHookipa Biotech GmbH
124 Previous Clinical Trials
21,819 Total Patients Enrolled
1 Trials studying Prostate Cancer
179 Patients Enrolled for Prostate Cancer
Head of Clinical DevelopmentStudy DirectorHookipa Biotech GmbH
4 Previous Clinical Trials
780 Total Patients Enrolled

Media Library

HB-302/HB-301 Alternating 2-Vector Therapy (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05553639 — Phase 1 & 2
Prostate Cancer Research Study Groups: HB-302/HB-301 Alternating 2-Vector Therapy Intravenously (IV)
Prostate Cancer Clinical Trial 2023: HB-302/HB-301 Alternating 2-Vector Therapy Highlights & Side Effects. Trial Name: NCT05553639 — Phase 1 & 2
HB-302/HB-301 Alternating 2-Vector Therapy (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05553639 — Phase 1 & 2
~5 spots leftby Oct 2025